12th Jul 2007 18:36
BTG PLC12 July 2007 For immediate release Annual Information Update 2006 BTG plc (LSE: BGC) ("the Company") is pleased to provide its annual informationupdate, in accordance with the requirements of the Prospectus Rule 5.2. Thisupdate refers to information that has been published or made available by theCompany to the public over the twelve months ending today. To avoid anunnecessarily lengthy document, information is referred to in this updaterather than included in full. The information referred to in this update was up to date at the time the information was published but some information may now be out-of-date. (1) Announcements made via RNS, a Regulatory Information Service All of the documents listed below were published via RNS, a RegulatoryInformation Service on or around the dates indicated. Date of publication Brief description of announcement 29 June 2007 Total Voting Rights and Share Capital20 June 2007 Annual Report and Accounts and AGM documents filed with UKLA15 June 2007 Directors' interests in shares of the company1 June 2007 Total Voting Rights and Share Capital24 May 2007 Preliminary results statement 30 April 2007 Total Voting Rights and Share Capital19 April 2007 BTG signs agreement with Novacea and KuDOS for AQ4N13 April 2007 BTG continues physical sciences divestment programme granting two licences to technology patents worth up to $46m2 April 2007 Close period update30 March 2007 Block listing six monthly return5 March 2007 Notification of major interest in shares28 February 2007 Total Voting Rights and Share Capital27 February 2007 BTG licensee Cougar Biotechnology presents positive data on prostrate cancer compound at ASCO symposium20 February 2007 BTG Acquires Novel Opioid Agonist for Post-Operative Pain Control from CLL Pharma 13 February 2007 Notification of major interest in shares22 January 2007 BTG's Plevitrexed Shows promising Efficacy and Tolerability in a Phase I/II study22 January 2007 Notification of major interest in shares19 January 2007 Total Voting Rights and Share Capital22 December 2006 Total Voting Rights and Share Capital22 December 2006 BTG Licenses haemofiltration device patents to Fresenius Medical Care21 December 2006 Notification of major interest in shares13 December 2006 Results of European Phase III Randomised Controlled Trial Comparing Varisolve (R) with Surgery or Sclerotherapy Published in Phlebology1 December 2006 Notification of major interest in shares30 November 2006 Notification of major interest in shares24 November 2006 Interim Report and Accounts filed with UKLA9 November 2006 Interim results statement3 November 2006 Notification of major interest in shares3 November 2006 Notification of major interest in shares3 November 2006 Notification of major interest in shares23 October 2006 Notification of major interest in shares11 October 2006 Notification of major interest in shares2 October 2006 Block listing six monthly return27 September 2006 BTG appoints Peter Chambre as a director25 September 2006 BTG completes sale of RFID patent portfolio 23 August 2006 Directors' interests in shares of the company17 August 2006 BTG Licensee TolerRX, Inc. Raises $35.6m to Develop TRX4; Phase III Pivotal Trial in Type 1 Diabetes Planned to Commence in 2006 16 August 2006 BTG sells online navigation tracking patents31 July 2006 Notification of major interest in shares26 July 2006 2006 AGM statement 26 July 2006 Results of AGM25 July 2006 Notification of major interest in shares 17 July 2006 Notification of major interest in shares12 July 2006 Annual Information Update 2006 Copies of the above announcements can be downloaded from the Company's website(www.btgplc.com) or obtained from the Company Secretary at the Company'sRegistered Office, 10 Fleet Place, Limeburner Lane, London, EC4M 7SB. (2) Documents filed at Companies House All of the documents listed below were filed with Companies House in Cardiff on or around the dates indicated. Date of filing Brief description of document 29 June 2007 Form 88(2) allotment of shares re share option exercise4 July 2007 Annual Report and Accounts, year ended 31 March 200730 March 2007 Form 88(2) allotment of shares re share option exercise1 February 2007 Form 88(2) allotment of shares re share option exercise16 January 2007 Form 363s Annual Return11 December 2006 Form 88(2) allotment of shares re share option exercise17 November 2006 Form 288a Peter Chambre appointed as a director31 October 2006 Form 88(2) allotment of shares re share option exercise4 August 2006 Form 288b relating to the retirement of Malcolm Coster as a director 3 August 2006 Form RES10 relating to allotment of securities 1 August 2006 Annual Report and Accounts, year ended 31 March 2006 Copies of documents filed at Companies House can be obtained from CompaniesHouse or obtained from the Company Secretary at the Company's Registered Office,10 Fleet Place, Limeburner Lane, London, EC4M 7SB. CONTACT: Andy BurrowsDirector of Investor Relations Telephone: 020 7575 1741 12 July 2007 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
BTG